BR0210266A - Pharmaceutical composition comprising a lipase inhibitor, process for preparing said composition, obesity treatment kit, use of the composition, obesity treatment process and lipase inhibitor - Google Patents

Pharmaceutical composition comprising a lipase inhibitor, process for preparing said composition, obesity treatment kit, use of the composition, obesity treatment process and lipase inhibitor

Info

Publication number
BR0210266A
BR0210266A BR0210266-8A BR0210266A BR0210266A BR 0210266 A BR0210266 A BR 0210266A BR 0210266 A BR0210266 A BR 0210266A BR 0210266 A BR0210266 A BR 0210266A
Authority
BR
Brazil
Prior art keywords
composition
lipase inhibitor
obesity treatment
preparing
pharmaceutical composition
Prior art date
Application number
BR0210266-8A
Other languages
Portuguese (pt)
Other versions
BRPI0210266B1 (en
Inventor
Karsten Maeder
Rainer Eugen Martin
Susanne Raab
Lukas Christoph Scheibler
Thomas Schindler
Marco Schroeder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0210266(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0210266A publication Critical patent/BR0210266A/en
Publication of BRPI0210266B1 publication Critical patent/BRPI0210266B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSIçãO FARMACêUTICA QUE COMPREENDE UM INIBIDOR DE LìPASES, PROCESSO PARA PREPARAR ESSA COMPOSIçãO, CONJUNTO PARA O TRATAMENTO DE OBESIDADE, UTILIZAçãO DA COMPOSIçãO, PROCESSO DE TRATAMENTO DE OBESIDADE E INIBIDOR DE LìPASES". A presente invenção refere-se a uma composição farmacêutica que compreende um inibidor de lípases, preferentemente orlistat, dotado de um ponto de fusão de <242>37<198>C, um éster de ácido graxo de sacarina em que o éster de ácido graxo de sacarina é um mono-, di-, tri- ou tetra-éster e, opcionalmente, um ou mais excipientes farmaceuticamente aceitáveis."PHARMACEUTICAL COMPOSITION UNDERSTANDING A LIPASE INHIBITOR, PROCESS FOR PREPARING THIS COMPOSITION, SET FOR OBESITY TREATMENT, USE OF COMPOSITION, OBESITY TREATMENT PROCESS". The present invention relates to a pharmaceutical composition comprising a lipase inhibitor, preferably orlistat, having a melting point of ≤ 37 ° C, a saccharin fatty acid ester wherein the fatty acid ester of saccharin is a mono-, di-, tri- or tetra ester and optionally one or more pharmaceutically acceptable excipients.

BRPI0210266A 2001-06-06 2002-05-29 a pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester, process for preparing such composition and use of the composition BRPI0210266B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01113793 2001-06-06
PCT/EP2002/005889 WO2002098412A1 (en) 2001-06-06 2002-05-29 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester

Publications (2)

Publication Number Publication Date
BR0210266A true BR0210266A (en) 2004-07-20
BRPI0210266B1 BRPI0210266B1 (en) 2016-01-26

Family

ID=8177654

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210266A BRPI0210266B1 (en) 2001-06-06 2002-05-29 a pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester, process for preparing such composition and use of the composition

Country Status (40)

Country Link
US (4) US20030027786A1 (en)
EP (1) EP1399152B1 (en)
JP (2) JP4261337B2 (en)
KR (1) KR100753729B1 (en)
CN (1) CN1514725B (en)
AR (1) AR034355A1 (en)
AT (1) ATE356622T1 (en)
AU (1) AU2002257817B2 (en)
BG (1) BG66346B1 (en)
BR (1) BRPI0210266B1 (en)
CA (1) CA2448030C (en)
CO (1) CO5540293A2 (en)
CY (1) CY1107641T1 (en)
CZ (1) CZ299948B6 (en)
DE (1) DE60218845T2 (en)
DK (1) DK1399152T3 (en)
EC (1) ECSP034871A (en)
ES (1) ES2282415T3 (en)
GT (1) GT200200106A (en)
HK (1) HK1067312A1 (en)
HR (1) HRP20030983B1 (en)
HU (1) HU230405B1 (en)
IL (2) IL158908A0 (en)
JO (1) JO2455B1 (en)
MA (1) MA27031A1 (en)
ME (1) ME00579B (en)
MX (1) MXPA03011191A (en)
MY (1) MY161871A (en)
NO (1) NO328006B1 (en)
NZ (1) NZ529630A (en)
PA (1) PA8546701A1 (en)
PE (1) PE20030230A1 (en)
PL (1) PL215266B1 (en)
PT (1) PT1399152E (en)
RS (1) RS50713B (en)
RU (1) RU2271808C2 (en)
SI (1) SI1399152T1 (en)
SK (1) SK287602B6 (en)
WO (1) WO2002098412A1 (en)
ZA (1) ZA200309007B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A (en) * 2004-03-15 2005-09-16 Bioferme Oy Functional food
KR100910000B1 (en) * 2005-05-13 2009-07-29 씨제이제일제당 (주) Pharmaceutical Compositions Containing Lipase Inhibitors
ES2434072T3 (en) * 2005-06-09 2013-12-13 Norgine Bv Solid preparation of 2-hexadecyloxy-6-methyl-4H-3,1-benzoxacin-4-one
US20070111914A1 (en) * 2005-11-16 2007-05-17 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Environmentally friendly laundry method and kit
KR101252635B1 (en) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 Pharmaceutical composition comprising a lipase inhibitor and a lipophilic oil absorbant and oral formulation prepared therefrom
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
PL216542B1 (en) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Production method of a stable Orlistat composition in form of encapsulated powder
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR2994386B1 (en) * 2012-08-07 2016-06-24 Thorel Jean-Noel INHIBITION OF ADHESION OF PATHOGENIC MICROORGANISMS BY SUCROSE AND / OR SORBITAN ESTER IN THE COSMETIC TREATMENT OF SKIN ATOPIA
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
CN104546768B (en) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 Chewing tablet composition containing lipase inhibitor and preparation method thereof
EP3364956A4 (en) 2015-10-23 2019-05-01 ERX Pharmaceuticals, Inc. Analogs of celastrol
CN113151373B (en) * 2021-03-09 2023-07-04 武汉臻治生物科技有限公司 Preparation method and application of sucrose monoester with antibacterial and antitumor activities
KR102637596B1 (en) 2022-03-18 2024-02-19 (주)보노보씨 Educational instrument of woodwork

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965133A1 (en) 1969-12-27 1971-07-22 Merck Patent Gmbh Bile acid and triglyceride absorbing resins
US4148924A (en) * 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
NL8600050A (en) 1986-01-13 1987-08-03 Sanico Nv PHARMACEUTICAL PREPARATION WITH DELAYED DELIVERY OF THE ACTIVE SUBSTANCE AND METHOD FOR PREPARING IT.
ATE91592T1 (en) * 1986-12-19 1993-08-15 Procter & Gamble NUTRITIONAL COMPOSITION WITH HIGHER BLOOD CHOLESTEROL LOWERING PROPERTIES.
JP2748597B2 (en) 1989-09-28 1998-05-06 三菱化学株式会社 Food deterioration inhibitor
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
JP3112473B2 (en) 1990-10-18 2000-11-27 オリンパス光学工業株式会社 Method of manufacturing refractive index distribution type optical element
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2735658B1 (en) * 1995-06-21 1997-09-12 Capsulis ENCAPSULATION OF COMPOUNDS FOR FOOD USE WITH SURFACTANTS
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
WO2000009122A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
TR200100472T2 (en) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and cytosan
WO2000025598A1 (en) 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025609A1 (en) * 1999-09-13 2002-12-04 Hoffmann La Roche SOLID LIPID FORMULATIONS
AR025587A1 (en) * 1999-09-13 2002-12-04 Hoffmann La Roche DISPERSION FORMULATIONS CONTAINING LIPASA INHIBITORS
AU1347701A (en) 1999-10-29 2001-05-14 John Jason Gentry Mullins Oxetanone derivatives
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
SI1296656T1 (en) * 2000-06-27 2006-12-31 Hoffmann La Roche Method for preparing a composition
KR100556324B1 (en) * 2000-07-28 2006-03-03 에프. 호프만-라 로슈 아게 A pharmaceutical composition comprising a lipase inhibitor and a bile acid sequestrant
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6534097B1 (en) * 2002-07-11 2003-03-18 Betty Baggott Pest repellent

Also Published As

Publication number Publication date
CZ299948B6 (en) 2009-01-07
HRP20030983B1 (en) 2011-10-31
NZ529630A (en) 2006-05-26
RS96003A (en) 2006-10-27
HRP20030983A2 (en) 2005-08-31
CA2448030A1 (en) 2002-12-12
DE60218845D1 (en) 2007-04-26
HUP0401208A3 (en) 2008-04-28
BG108421A (en) 2005-02-28
ZA200309007B (en) 2005-04-26
US8343543B2 (en) 2013-01-01
IL158908A0 (en) 2004-05-12
CN1514725B (en) 2010-04-21
US8039508B2 (en) 2011-10-18
PL366890A1 (en) 2005-02-07
JP4261337B2 (en) 2009-04-30
PA8546701A1 (en) 2003-01-24
BRPI0210266B1 (en) 2016-01-26
ATE356622T1 (en) 2007-04-15
NO20035318D0 (en) 2003-11-28
CZ20033525A3 (en) 2004-04-14
CA2448030C (en) 2009-11-24
RS50713B (en) 2010-06-30
SK287602B6 (en) 2011-03-04
IL158908A (en) 2008-08-07
RU2003136728A (en) 2005-05-20
GT200200106A (en) 2003-02-11
SI1399152T1 (en) 2007-08-31
ME00579A (en) 2011-12-20
HUP0401208A2 (en) 2004-11-29
KR100753729B1 (en) 2007-08-30
DE60218845T2 (en) 2008-01-03
AR034355A1 (en) 2004-02-18
EP1399152B1 (en) 2007-03-14
JO2455B1 (en) 2008-10-09
JP2004532271A (en) 2004-10-21
US20110301231A1 (en) 2011-12-08
CO5540293A2 (en) 2005-07-29
PT1399152E (en) 2007-06-05
JP2009108076A (en) 2009-05-21
NO328006B1 (en) 2009-11-09
DK1399152T3 (en) 2007-06-18
SK16092003A3 (en) 2004-05-04
HK1067312A1 (en) 2005-04-08
RU2271808C2 (en) 2006-03-20
EP1399152A1 (en) 2004-03-24
WO2002098412A1 (en) 2002-12-12
PL215266B1 (en) 2013-11-29
ES2282415T3 (en) 2007-10-16
BG66346B1 (en) 2013-08-30
CY1107641T1 (en) 2013-04-18
US20050101562A1 (en) 2005-05-12
ECSP034871A (en) 2004-01-28
CN1514725A (en) 2004-07-21
KR20040010689A (en) 2004-01-31
HU230405B1 (en) 2016-04-28
MA27031A1 (en) 2004-12-20
ME00579B (en) 2011-12-20
US20030027786A1 (en) 2003-02-06
US20130079391A1 (en) 2013-03-28
MXPA03011191A (en) 2004-02-26
PE20030230A1 (en) 2003-03-17
MY161871A (en) 2017-05-15
AU2002257817B2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
BR0210266A (en) Pharmaceutical composition comprising a lipase inhibitor, process for preparing said composition, obesity treatment kit, use of the composition, obesity treatment process and lipase inhibitor
UY29919A1 (en) SUBSTITUTED DERIVATIVES OF 3,4-DIHYDROISOQUINOLIN-1-AMINO-TRIFLUOROACETATE, ITS PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS
UY30025A1 (en) SUBSTITUTED DERIVATIVES OF 2-AMINO-5,6-DIHIDRO PIRIMIDIN-4 (3H) -ONAS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING AND APPLICATIONS.
BR0010555A (en) Neuraminidase Inhibitors
BR0112799A (en) Pharmaceutical composition, process for preparation and use thereof, assembly and process for treating obesity, use of a lipase inhibitor and bile acid sequestrant, and process for treating or preventing gastrointestinal side effects
BR0113776A (en) Composition of selected fused pyrrolocarbazoles and method for treating and preventing various diseases using said composition
HUP0303083A2 (en) Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use
BR0210384A (en) Multi-cyclic quinuclidine-substituted heteroaryl for the treatment of disease
BR0210267A (en) Solid pharmaceutical composition, process for preparing same, obesity treatment set, composition use, obesity treatment process and lipase inhibitor
BR0016164A (en) Compound, pharmaceutical composition, use of a compound, and, methods for the treatment and / or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (crohn&#39;s disease), inflammatory dermatological disorders and proliferative, psoriasis, atopic dermatitis, uveitis, septic shock, AIDS and osteoporosis and for the treatment of acne
BR0206955A (en) Cannabinoid Receptor Binders
BR0212378A (en) 17betahydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BR9712530A (en) Interleukin-1beta converting enzyme asparate ester inhibitors
BRPI0607555A2 (en) inhibitors of triglyceride transfer microsomal protein and apo-b secretion
UY30274A1 (en) SUBSTITUTED DERIVATIVES OF THE N- (4-METHYL-1,3-TIAZOL-2-IL) GUANIDINE, PHARMACEUTICAL FORMULATIONS CONTAINING IT AND APPLICATIONS
BRPI0409627A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
HN2002000198A (en) PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN
BRPI0111140B8 (en) polymorphic form, use thereof, and pharmaceutical composition
EA200401183A1 (en) APPLICATION OF IL-18 INHIBITORS AS A DIAGNOSTIC MARKER
BRPI0414299A (en) Modafinil Modified Release Pharmaceutical Compositions
AR039664A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY A LIPASE AND GLUCOMANAN INHIBITOR
BRPI0510451A (en) compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or preventing diseases that are modulated by ppar (delta) and / or ppar (alpha) agonists and their use
BR0208999A (en) Process for the preparation of cefpodoxima acid
BR0111767A (en) Analgesic and anti-inflammatory compositions containing cox-2 inhibitors, their use and method for enhancing an analgesic compound
PT1347960E (en) PROCESS FOR THE PREPARATION OF (+) - TRANS-4-P-FLUOROPHENYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINE

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.